Outcomes After Accelerated Partial Breast Irradiation in Patients With ASTRO Consensus Statement Cautionary Features

McHaffie, Derek R.; Patel, Rakesh; Adkison, Jarrod B.; Das, Rupak K.; Geye, Heather M.; Cannon, George M.

doi:10.1016/j.ijrobp.2010.05.011

Cited by 56 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other series similarly showed a 0% 5-year IBTR risk among 32 women with DCIS treated with multicatheter brachytherapy. 18 In contrast, one single-institution investigation reported a trend toward higher risk of time to IBTR among pure DCIS tumors compared with invasive ductal carcinomas at 4 years after MammoSite (hazard ratio, 3.57; P = .06). 19 One prospective multicenter trial using MammoSite in 41 DCIS patients showed a 9.8% 5-year risk of IBTR, all outside the treatment field.…”

Section: Pure Dcismentioning

confidence: 89%

Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement

Correa

Harris

Leonardi

et al. 2017

Practical Radiation Oncology

519

342

View full text Add to dashboard Cite

Section: Pure Dcismentioning

confidence: 89%

Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement

Correa

Harris

Leonardi

et al. 2017

Practical Radiation Oncology

519

342

View full text Add to dashboard Cite

“…The groupings were based primarily on an analysis of the characteristics of patients most frequently included in trials of APBI and not on data that identified subsets of patients with higher rates of ipsilateral breast tumor recurrence (IBTR) when treated with APBI. Recent analysis using ASBS registry trial [139,140] and using data from using of University of Wisconsin [141] show that the ASTRO consensus groupings may not be optimal in identifying patients for APBI.…”

Section: Discussionmentioning

confidence: 99%

Accelerated Partial Breast Irradiation (APBI): A review of available techniques

2010

View full text Add to dashboard Cite

Breast conservation therapy (BCT) is the procedure of choice for the management of the early stage breast cancer. However, its utilization has not been maximized because of logistics issues associated with the protracted treatment involved with the radiation treatment. Accelerated Partial Breast Irradiation (APBI) is an approach that treats only the lumpectomy bed plus a 1-2 cm margin, rather than the whole breast. Hence because of the small volume of irradiation a higher dose can be delivered in a shorter period of time. There has been growing interest for APBI and various approaches have been developed under phase I-III clinical studies; these include multicatheter interstitial brachytherapy, balloon catheter brachytherapy, conformal external beam radiation therapy and intra-operative radiation therapy (IORT). Balloon-based brachytherapy approaches include Mammosite, Axxent electronic brachytherapy and Contura, Hybrid brachytherapy devices include SAVI and ClearPath. This paper reviews the different techniques, identifying the weaknesses and strength of each approach and proposes a direction for future research and development. It is evident that APBI will play a role in the management of a selected group of early breast cancer. However, the relative role of the different techniques is yet to be clearly identified.

show abstract

“…7,88,89 The NSABP/ RTOG trial should help shine some light on the growing number of groups with data that does not correlate well with the expected outcomes of the ASTRO consensus statement groupings, [76][77][78][79][80][81] and our current understanding of appropriate patient selection criteria. The trial is closed to low-risk groupings, having accrued 4,169 patients as of October 2012 of the needed 4,300 to complete accrual.…”

Section: Discussion Of Datamentioning

confidence: 99%

Current modalities of accelerated partial breast irradiation

Cox

Swanson

2013

Nat Rev Clin Oncol

View full text Add to dashboard Cite

The benefits of adjuvant whole-breast irradiation (WBI) after breast-conserving surgery are well established and WBI is a standard of care. In selected patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has emerged as an alternative treatment option to WBI. Early trials of APBI have demonstrated an excellent local control rate and an associated good-to-excellent cosmetic outcome. APBI can reduce both the treatment volume and overall treatment time of adjuvant radiation therapy, which potentially overcomes logistical barriers associated with WBI that have previously prevented eligible women from pursuing breast-conserving therapy. Likewise, the addition of new modalities for APBI delivery has increased the number of patients who might be eligible for this adjuvant treatment-in the setting of breast-conserving surgery-despite the limited availability of long-term data on APBI outcomes compared to historical WBI outcomes. Ongoing phase III trials aim to compare APBI with WBI and also point the practitioner to the appropriate APBI patient selection criteria. Here, we review available modalities, patient selection criteria and consensus guideline recommendations, and current controversies in APBI.

show abstract

Outcomes After Accelerated Partial Breast Irradiation in Patients With ASTRO Consensus Statement Cautionary Features

Cited by 56 publications

References 22 publications

Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement

Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement

Accelerated Partial Breast Irradiation (APBI): A review of available techniques

Current modalities of accelerated partial breast irradiation

Contact Info

Product

Resources

About